US3366652A - Novel 17-ethers of 19-nortestosterone - Google Patents

Novel 17-ethers of 19-nortestosterone Download PDF

Info

Publication number
US3366652A
US3366652A US310465A US31046563A US3366652A US 3366652 A US3366652 A US 3366652A US 310465 A US310465 A US 310465A US 31046563 A US31046563 A US 31046563A US 3366652 A US3366652 A US 3366652A
Authority
US
United States
Prior art keywords
estr
ether
hydroxyethoxy
ethers
methoxyestra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US310465A
Inventor
Gerhard R Wendt
Kurt W Ledig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Priority to US310465A priority Critical patent/US3366652A/en
Application granted granted Critical
Publication of US3366652A publication Critical patent/US3366652A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Definitions

  • This invention relates in general to novel compositions of matter classified in the art of chemistry as steroids and methods for manufacturing and using such compositions.
  • R represents either hydrogen or a lower alkyl group such as methyl, ethyl, or propyl, for example, which are preferred, but which may also include other lower alkyl groups containing up to about 7 carbon atoms such as isopropyl, butyl, isobutyl and the like radicals.
  • the compounds or the present invention in their tangible embodiment form as well as their graphic representation as shown above, are considered useful steroidal anabolic agents which have particular eflicacy because of their low androgenic activity in concert with a favorable anabolic activity.
  • the tangible embodimnets of the compositions represented by Formula II are also active progestational agents.
  • those compounds wherein R represents hydrogen have demonstrated a satisfactory level of progestational activity when evaluated in test animals.
  • some of the compounds of both series are hormones, specifically exhibiting anti-inflammatory activity as well as being useful for their general hormonal properties.
  • lower alkyl radicals is intended to refer to those alkyl groups which include both straight and branch chain alkyl radicals, among which are the alkyl radicals specifically noted above as well as the cycloalkyl lower alkyl radicals, cyclohexyl and cyclopentyl, which would be expected to perform in a like manner.
  • a typical starting material for the preparation of the compounds of this invention such as the typical starting material 175- (2-hydroxyethoxy) -3-methoxyestra- 1,3,5 10) -triene may be prepared by hydrogenolysis of the corresponding 17, 17-ethylene ketal analogs with a suitable reducing agent, but preferably with one such as lithium aluminum hydride aluminum chloride, as more particularly detailed therein.
  • the nature of the 17-ether group of the end product obtained can be controlled by the selection of a suitable 17,17-a1ky1ene ketal starting material.
  • the 17,17-ethylene ketal would be the compound, 3-methoxy-17,l7-ethylenedioxyestra-1, 3,5 (10)-triene.
  • the 17-hydroxyalkyl ethers obtained in the first step may be further reacted with a suitable alkylating agent such as diazomethane and the like by the use of conventional alkylation technique as more particularly described in our aforesaid copending application, Ser. No.
  • the 17-ketone (A), be lower alkyl, cycloalkyl and the like is the 17-ketal (B), detail.
  • the crude enol ether product obtained from the reduction step is designated as product (D) in the following flow sheet.
  • product (D) When (D) is treated with a weak acid such as oxalic acid, the ether group in position 3 is transformed into a keto group to produce compound (Ia)17/8-(2-hydroxy ethoxy)estr-5(l0)-en-3-one.
  • a compound of type (Ila) which has a 4(5) double bond rather than a 5 (10) double bond, may be obtained by treatment of (la) with a suitable strong acid/methanol solution to shift the double bond.
  • (Ha) may be directly obtained by acid hydrolysis of (D) with a strong acid.
  • the symbol R represents either hydrogen or a lower alkyl group.
  • the 4(5)-A-ring unsaturated compounds can be obtained directly by hydrolysis of a 2,5(l0)-diene such as the compound 17-(2-hydroxyethoxy)-3-methoxyestra-2,5(10)-diene by treatment with a strong acid such as hydrochloric acid to obtain a compound such as 17/3-(2-hydroxyethoxy)estr-4-en-3-one.
  • a strong acid such as hydrochloric acid
  • Example 2 7 5- (Z-methoxyeth oxy) estr-5 (1 0 -en- 3 -one Treat a mixture of 2.5 g. of d-l7fi-(2-methoxyethoxy)- 3-methoxyestra-l,3,5(l0)-triene, 75 ml. of 1-methoxy-2- propanol, 75 ml. of tetrahydrofuran and 300 ml. of ammonia with 2.5 g. of lithium during 30 minutes. After adding 20 ml. of absolute alcohol followed by 2.5 g. of ammonium chloride, precipitate the product with water to yield 1.5 g. of the enol ether; I.R. 5.6; 6.0 U.V. essentially no aromatic.
  • Example 3 --d-1 7t3-(Z-ethoxyethoxy estr-5 (10 -en-3-0ne Substitute d-17t3-(2-methoxyethoxy) 3 methoxyestra- 1,3,5(10)-triene with d-3-butoxy-17B-(2- ethoxyethoxy) estra-1,3,5(10)-triene, and carry out the reaction as described for Example 2, d-175-(2-ethoxyethoxy estr-5(l0)- en-3-one is obtained.
  • Example 4 75- (Z-hy droxyethoxy estr-4-en-3 -one
  • Example 5 -d-l 7,8- (Z-hydroxyethoxy estr-4-en-3-0ne
  • d-IZB-(Z-hydroxyethoxy) estr-S 10) -en- 3-one with a solution methanol, hydrochloric acid, and water, using the method outlined in Example 7, d-17/3-(2- hydroxyethoxy)estr-4-en-3-one can be obtained.
  • Example 7. ---d 75- (Z-m ethoxyethoxy estr-4-en-3-0ne mg. of the product; M.P. 73-75"; UV. 241 my (6 16,900); LR. 5.96; 6.20 7.
  • Example 8.d-J7fi- (Z-ethoxyetho xy estr-4-en-3-0ne) Substitute d-17,8-(2-methoxyethoxy) 3 methoxyestra- 1,3,5 1 0)-triene with d-B-butoxy-17fi-(2-ethoxyethoxy) estra-1,3,5(10)-triene and carry out the reaction as outlined in the procedure of Example 2, the 1,4-dihydr0 compound can be obtained.
  • a 17-ether of a steroid selected from the group consisting of those having one of the general structural formulae:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Description

United States Patent 3,366,652 NOVEL 17-ETHERS OF 19-NORTESTOSTERONE Gerhard R. Wendt, Havertown, and Kurt W. Lcdig,
Philadelphia, Pa., assignors to American Home Products Corporation, New York, N.Y., a corporation of Delaware No Drawing. Filed Sept. 20, 1963, Ser. No. 310,465 5 Claims. (Cl. 260397.4)
This invention relates in general to novel compositions of matter classified in the art of chemistry as steroids and methods for manufacturing and using such compositions.
The invention which applicants desire to patent in its chief product aspect is particularly concerned with the concept and physical embodiment of a series of novel 17- ethers of 19-nortestosterone and its functional equivalents such as the corresponding 17-ethers of its 5(10)-3-one analogs. Typically compounds which fall within the metes and bounds of applicants invention are those having the general Formulae I and II:
wherein the symbol R represents either hydrogen or a lower alkyl group such as methyl, ethyl, or propyl, for example, which are preferred, but which may also include other lower alkyl groups containing up to about 7 carbon atoms such as isopropyl, butyl, isobutyl and the like radicals.
The compounds or the present invention in their tangible embodiment form as well as their graphic representation as shown above, are considered useful steroidal anabolic agents which have particular eflicacy because of their low androgenic activity in concert with a favorable anabolic activity. Moreover the tangible embodimnets of the compositions represented by Formula II are also active progestational agents. In particular those compounds wherein R represents hydrogen have demonstrated a satisfactory level of progestational activity when evaluated in test animals. In addition to the aforesaid uses, some of the compounds of both series are hormones, specifically exhibiting anti-inflammatory activity as well as being useful for their general hormonal properties.
As employed herein, the term lower alkyl radicals is intended to refer to those alkyl groups which include both straight and branch chain alkyl radicals, among which are the alkyl radicals specifically noted above as well as the cycloalkyl lower alkyl radicals, cyclohexyl and cyclopentyl, which would be expected to perform in a like manner.
Our preferred manner of making and using our invention will be generally described so as to enable one versed in the art of chemistry to make and use the embodiments thereof as follows:
(a) Preparation of starting materials.-As generally and particularly described and claimed in our copending application Ser. No. 310,485 filed Sept. 20, 1963, a typical starting material for the preparation of the compounds of this invention such as the typical starting material 175- (2-hydroxyethoxy) -3-methoxyestra- 1,3,5 10) -triene may be prepared by hydrogenolysis of the corresponding 17, 17-ethylene ketal analogs with a suitable reducing agent, but preferably with one such as lithium aluminum hydride aluminum chloride, as more particularly detailed therein.
"ice
In this preparation the nature of the 17-ether group of the end product obtained can be controlled by the selection of a suitable 17,17-a1ky1ene ketal starting material. In the instant case, illustratively, the 17,17-ethylene ketal would be the compound, 3-methoxy-17,l7-ethylenedioxyestra-1, 3,5 (10)-triene. Moreover, if it is desired to obtain final products wherein the ether group in position 17 is an alkyloxyalkyl radical, the 17-hydroxyalkyl ethers obtained in the first step may be further reacted with a suitable alkylating agent such as diazomethane and the like by the use of conventional alkylation technique as more particularly described in our aforesaid copending application, Ser. No. 310,485. The 17-ketals of 1,3,5 (10)estratrienes from which the 17-ethers of 1,3,5 (10)-estratrienes are prepared are themselves manufactured as disclosed in H. Smith et a1. copending application Ser. No. 219,135, filed Aug. 24, 1962, now Patent No. 3,138,588. In the Smith application, the 17,17-substituted alkylenedioxy type analogs are prepared from the corresponding 17- ketones by treatment under conventional ketalizing conditions. A typical general reaction would be the following:
In the above reaction, the 17-ketone (A), be lower alkyl, cycloalkyl and the like is the 17-ketal (B), detail.
As indicated above generally and more particularly in S.N. 310,485 filed Sept. 20, 1963, a steroidal 17-ketal of SN. 219,135 illustrated by compounds of structure (B) above is reduced to the 17-ether alcohol, which affords the starting compounds for this particular invention. The 17-position substituted 1,3,5 (10)-estratriene compounds of SN. 219,135 and SN. 310,485 are not included as the subject matter of this invention and are noted herein for completeness of disclosure, since these separately inventive materials are separately disclosed and claimedin the aforesaid copending applications referred to above.
(b) Preparation of final products.-In our preferred mode of synthesis the starting materials of the type illustrated in our S.N. 310,485 such as the typical starting compound 17 3-(2-hydroxyethoxy)-3-methoxyestra 1,3, 5(10)-triene (C), is selectively A-ring reduced with a suitable reducing agent, preferably lithium and l-methoxy-2-propanol, in a suitable organic reaction solvent such as liquid ammonia with constant agitation (as in Example 1 below). It may be noted that in addition to the reaction solvent employed, cosolvents such as tetrahydrofuran may be used (as stated in Example 2 below). The crude enol ether product obtained from the reduction step is designated as product (D) in the following flow sheet. When (D) is treated with a weak acid such as oxalic acid, the ether group in position 3 is transformed into a keto group to produce compound (Ia)17/8-(2-hydroxy ethoxy)estr-5(l0)-en-3-one. A compound of type (Ila), which has a 4(5) double bond rather than a 5 (10) double bond, may be obtained by treatment of (la) with a suitable strong acid/methanol solution to shift the double bond. Alternately, (Ha), may be directly obtained by acid hydrolysis of (D) with a strong acid.
wherein R may transformed to as noted in Ser. No. 219,135 in greater 3 These reactions may be generally represented:
O O(OH2)2OR lBEDUCTIoN D (CH1)2OR IHYDROLYSIS I8 O(GH2)2OR (l) (CHDzO R A l A o 0 'lISOMERIZATION 11a O(OH2)2OR In a similar manner, those analogs wherein the 17-ether group is of the alkyloxyalkyl type may be obtained by selection of a suitably substituted (C) type starting material, with R representing an alkyl group.
In the above reaction sequence, the symbol R represents either hydrogen or a lower alkyl group. The symbol R, where it appears, represents a lower alkyl group.
In an alternate method of preparation as specifically illustrated in Example 4 below, the 4(5)-A-ring unsaturated compounds can be obtained directly by hydrolysis of a 2,5(l0)-diene such as the compound 17-(2-hydroxyethoxy)-3-methoxyestra-2,5(10)-diene by treatment with a strong acid such as hydrochloric acid to obtain a compound such as 17/3-(2-hydroxyethoxy)estr-4-en-3-one.
These and other like variants of our inventive concept will undoubtedly occur to those skilled in the art and are intended to be included within the metes and bounds of our inventive concept.
The following several examples will illustrate the preferred mode of operation of our invention. However, they are purely intended for purpose of illustration, and may not be construed to limit the concept involved in any manner. For a legal definition of the scope of the inven tion, attention may be directed only to the several appended claims.
Example 1.d-1 7p- (Z-hydroxyethoxy estr- (10 -en- 3 -one Treat a mixture of 2.9 g. of d-17fi-(2-hydroxyethoxy) 3-methoxyestra-l,3,5(10)-triene, 100 ml. of l-methoxy-Z- propanol and 300 ml. of liquid ammonia with 3.0 g. of
lithium during 30 minutes while stirring. After adding 6.0 g. of ammonium chloride and water, 'filter oif the enol ether and dry in vacuo to yield 2.1 g.; I.R. 3.0; 5.9; 6.0 t; U.V. essentially no aromatic.
Add a 700 mg. sample of the enol ether to a solution of 1.0 g. of oxalic acid dihydrate, 10 ml. of water, and 50 ml. of methanol, and stir for 2 hours under nitrogen. Dilute the reaction mixture with Water and extract with ether. Recrystallize the residue obtained after evaporation of the solvent from ethylacetate-hexane to yield 300 mg. of d-17fi-(2-hydroxyethoxy)estr 5(10) en 3-one; MP. 8488.
Found: C, 75.72; H, 9.48. (3 1-1 0 C, 75.43; H, 9.50.
Example 2 .-d-] 7 5- (Z-methoxyeth oxy) estr-5 (1 0 -en- 3 -one Treat a mixture of 2.5 g. of d-l7fi-(2-methoxyethoxy)- 3-methoxyestra-l,3,5(l0)-triene, 75 ml. of 1-methoxy-2- propanol, 75 ml. of tetrahydrofuran and 300 ml. of ammonia with 2.5 g. of lithium during 30 minutes. After adding 20 ml. of absolute alcohol followed by 2.5 g. of ammonium chloride, precipitate the product with water to yield 1.5 g. of the enol ether; I.R. 5.6; 6.0 U.V. essentially no aromatic.
Add the enol ether to a solution of 2.0 g. of oxalic acid dihydrate in 20 ml. of water and ml. of methanol, and stir the reaction mixture under nitrogen for 2 hours. After adding Water, extract the product with ether. Wash the organic layer with a saturated sodium bicarbonate solution, followed by brine, and finally dry over magnesium sulfate. On evaporation of the ether, 17B-(2-methoxyethoxy)estr-5(10)-en-3-one can be obtained. LR. 5.75,u.
Example 3.--d-1 7t3-(Z-ethoxyethoxy estr-5 (10 -en-3-0ne Substitute d-17t3-(2-methoxyethoxy) 3 methoxyestra- 1,3,5(10)-triene with d-3-butoxy-17B-(2- ethoxyethoxy) estra-1,3,5(10)-triene, and carry out the reaction as described for Example 2, d-175-(2-ethoxyethoxy estr-5(l0)- en-3-one is obtained.
Example 4 .d-] 75- (Z-hy droxyethoxy estr-4-en-3 -one Add a 2.1 g. sample of d-17/3(2-hydroxyethoxy)-3- methoxyestra-2,5(10)-diene to a solution of ml. of methanol, 8 ml. of concentrated hydrochloric acid, and 5 ml. of water. Stire for 30 minutes, dilute the resulting clear solution with water and extract with ether. Wash the organic layer with saturated sodium bicarbonate solution and brine, and finally dry over magnesium sulfate. After evaporation of the solvent, recrystallize the crude product from acetone-petroleum ether to yield 1.1 g. of d-17fl-(2- hydroxyethoxy)estr-4-en-3-one; MP. ll3-ll4; LR. 2.90; 6.00; 6.18 2; U.V. 241 III/L (6 15,600).
Found: C, 75.15; H, 9.48. C H O requires: C, 75.43; H, 9.50%.
Example 5 .-d-l 7,8- (Z-hydroxyethoxy estr-4-en-3-0ne When treating d-IZB-(Z-hydroxyethoxy) estr-S 10) -en- 3-one with a solution methanol, hydrochloric acid, and water, using the method outlined in Example 7, d-17/3-(2- hydroxyethoxy)estr-4-en-3-one can be obtained.
When treating d-l7B (2-methoxyethoxy) 3 methoxyestra-2,5(l0)-diene with a solution of methanol, hydrochloric acid, and water by applying the procedure outlined in Example 4, d-l7,8-(2-methoxyethoxy)estr 4-en-3-one can be obtained.
Example 7.---d 75- (Z-m ethoxyethoxy estr-4-en-3-0ne mg. of the product; M.P. 73-75"; UV. 241 my (6 16,900); LR. 5.96; 6.20 7.
Found: C, 75.92; H, 9.55. C H O C, 75.86; H, 9.70%.
Example 8.d-J7fi- (Z-ethoxyetho xy estr-4-en-3-0ne Substitute d-17,8-(2-methoxyethoxy) 3 methoxyestra- 1,3,5 1 0)-triene with d-B-butoxy-17fi-(2-ethoxyethoxy) estra-1,3,5(10)-triene and carry out the reaction as outlined in the procedure of Example 2, the 1,4-dihydr0 compound can be obtained.
When treating this compound with a solution of methanol and aqueous hydrochloric acid using the procedure outlined in Example 4, d-17,B-(2-ethoxyethoxy)estr-4-en- 3-one can be obtained.
We claim:
1. A 17-ether of a steroid selected from the group consisting of those having one of the general structural formulae:
and
0 (CH2)BOH wherein R is lower alkyl.
References Cited Colton: J. Am. Chem. Soc. (1957), vol. 79, p. 1123 or Steroid Reactions by Djerassi p. 276 (1963), Holden- Day Inc. San Francisco, Calif.
ELBERT L. ROBERTS, Primary Examiner.

Claims (1)

1. A 17-ETHER OF A STEROID SELECTED FROM THE GROUP CONSISTING OF THOSE HAVING ONE OF THE GENERAL STRUCTURAL FORMULAE:
US310465A 1963-09-20 1963-09-20 Novel 17-ethers of 19-nortestosterone Expired - Lifetime US3366652A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US310465A US3366652A (en) 1963-09-20 1963-09-20 Novel 17-ethers of 19-nortestosterone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US310465A US3366652A (en) 1963-09-20 1963-09-20 Novel 17-ethers of 19-nortestosterone

Publications (1)

Publication Number Publication Date
US3366652A true US3366652A (en) 1968-01-30

Family

ID=23202636

Family Applications (1)

Application Number Title Priority Date Filing Date
US310465A Expired - Lifetime US3366652A (en) 1963-09-20 1963-09-20 Novel 17-ethers of 19-nortestosterone

Country Status (1)

Country Link
US (1) US3366652A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3475463A (en) * 1966-07-11 1969-10-28 Sterling Drug Inc 15,16-unsaturated 19-norsteroids and their preparation
US3929844A (en) * 1970-04-24 1975-12-30 Ciba Geigy Corp 3-Cyclopentyl ethers of 7{60 -methyl estrone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3475463A (en) * 1966-07-11 1969-10-28 Sterling Drug Inc 15,16-unsaturated 19-norsteroids and their preparation
US3929844A (en) * 1970-04-24 1975-12-30 Ciba Geigy Corp 3-Cyclopentyl ethers of 7{60 -methyl estrone

Similar Documents

Publication Publication Date Title
US3262949A (en) 7-methyl androstane compounds
RU2242479C2 (en) Compounds, set, androgenic composition
US3356573A (en) 17alpha-acyloxy-6-methylpregna-4, 6-diene-3, 20-diones and method for preparation of these and related 6-methyl-3-oxo-delta4, 6-steroids
US3362968A (en) 10alpha-methyl, 9beta-steroids of the androstane series
US3366652A (en) Novel 17-ethers of 19-nortestosterone
US2782193A (en) Process for the preparation of 16alpha, 17alpha-oxido-delta5-pregnene-3beta-ol-20-one
US3275666A (en) 16-methylene steroids of the esterne series
US3013025A (en) 17-hydroxy steroids and methods of making same
US3574197A (en) Process of producing 1-hydroxy-7alpha-methyl-estradiol derivatives
JP4749550B2 (en) 14β, 17α-hydroxymethylandrostane derivatives as androgens
US3107257A (en) 17alpha-(2-alkenyl)estra-1, 3, 5(10)-triene-3, 17beta-diols and esters thereof
US2713061A (en) 3-methyl androstanes
US3875188A (en) 17-Beta-alpha-lower alkyl allene-substituted steroids
US3050518A (en) 5-cyano and 5-carbamyl steroid derivatives
US3086033A (en) 1-methyl-17-alkyl-11-oxygenated delta1, 3, 5 (10)-estrogenic compounds
US2888468A (en) Process for the production of delta5-3-keto and delta4-3-keto steroids
US3028401A (en) 6-fluoro-19-nor-testosterone derivatives
US3055920A (en) 2-hydroxymethyl-delta2-androsten derivatives and process
US3062843A (en) C-2-carboxylic acid and c-2-hydroxymethyl derivatives of the androstane series
US2947762A (en) 2-aralkyl derivatives of delta4-pregnene-3, 20-dione and process for their production
US3709878A (en) 8 alpha-methyl-substituted-steroids
US3282929A (en) Method for preparation of aromatic a ring steroids
US3658853A (en) 17alpha-(2-alkynyl)-11beta-methylestra-1 3 5(10)-triene-3 17beta-diols and esters thereof
US3442891A (en) Steroidal 4,6-dien-3-ones having c6 substituents and process for preparing same
US3080395A (en) 2-halo methyl derivatives of the androstane series